A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology Revised Protocol Number 04, incorporating Amendment 05 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0, dated 07-Jan-09)

Trial Profile

A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology Revised Protocol Number 04, incorporating Amendment 05 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0, dated 07-Jan-09)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Pegdinetanib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov record.
    • 11 Oct 2012 Planned number of patients changed from 254 to 282.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top